Brief: Quince Therapeutics Receives U.S. FDA Fast Track Designation For EryDex System
03/06/2024 14:24
June 3 (Reuters) - Quince Therapeutics Inc QNCX.O :
* QUINCE THERAPEUTICS RECEIVES U.S. FDA FAST TRACK
DESIGNATION FOR
ERYDEX SYSTEM
Source text for Eikon: ID:nBw91gv14a
Further company coverage: QNCX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on IRulya Therapeutics
See all newsBrief: Quince Therapeutics - Changes Name To Irulya Therapeutics
Brief: Quince Therapeutics - Appoints Brigette Roberts As CEO Effective October 8, 2026
Quince Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Quince Therapeutics Reports Second Quarter 2026 Financial Results And Corporate Update
Quince Therapeutics Q2 net loss widens on acquisition charges